PMID- 32748714 OWN - NLM STAT- MEDLINE DCOM- 20211104 LR - 20220422 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 54 IP - 5 DP - 2020 Oct TI - Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer. PG - 401-407 LID - 10.1080/21681805.2020.1798502 [doi] AB - OBJECTIVE: To assess prostate cancer-specific and overall survival in prostate cancer patients with or without preexisting type 2 diabetes mellitus (T2DM) with regards to metformin use. METHODS: Patients diagnosed with prostate cancer in the Lithuanian population between 2001 and 2005 were identified through the Lithuanian Cancer Registry and followed until 2016, date of death, loss to follow-up or whichever came first. Information regarding the diagnosis of T2DM and antihyperglycemic medications were obtained from the National Health Insurance Fund database. Prostate cancer-specific and overall survival outcomes were analysed using univariate and multivariate Cox proportional hazard models. RESULTS: Out of 6689 men included, 254 (3.8%) had preexisting T2DM. There were 4807 deaths during follow-up, including 2084 from prostate cancer. No differences were found in prostate cancer-specific survival between men with or without T2DM. The risk of overall mortality was higher (HR = 1.24, 95% CI = 1.07-1.43) in diabetic men. Univariate analysis showed cancer stage at diagnosis and age to be significant predictors of survival. After adjustment for age and stage at diagnosis, there was no difference in prostate-specific survival between non-diabetic patients compared to metformin users or metformin non-users. However, overall survival was lower in T2DM patients, with a higher mortality risk for metformin non-users (HR = 1.63, 95% CI = 1.27-2.10). Prostate cancer-specific mortality risk was insignificantly lower in diabetic men on metformin (HR = 0.74, 95% CI = 0.54-1.02). CONCLUSION: There was no difference in long-term prostate cancer-specific survival in patients with or without T2DM. Overall survival was lower in T2DM patients not treated with metformin. FAU - Linkeviciute-Ulinskiene, Donata AU - Linkeviciute-Ulinskiene D AD - Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. FAU - Patasius, Ausvydas AU - Patasius A AUID- ORCID: 0000-0003-3874-2723 AD - Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania. AD - Department of Public Health, Institute of Health Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. FAU - Kincius, Marius AU - Kincius M AD - Department of Oncourology, National Cancer Institute, Vilnius, Lithuania. FAU - Zabuliene, Lina AU - Zabuliene L AD - Clinic of Rheumatology, Orthopaedics, Traumatology and Reconstructive Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. FAU - Smailyte, Giedre AU - Smailyte G AD - Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania. AD - Department of Public Health, Institute of Health Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. LA - eng PT - Journal Article DEP - 20200804 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Hypoglycemic Agents) RN - 9100L32L2N (Metformin) SB - IM MH - *Diabetes Mellitus, Type 2/complications/drug therapy MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - Male MH - Metformin/therapeutic use MH - *Prostatic Neoplasms/complications/drug therapy OTO - NOTNLM OT - Diabetes mellitus OT - hazard ratios OT - metformin OT - prostate cancer OT - survival EDAT- 2020/08/05 06:00 MHDA- 2021/11/05 06:00 CRDT- 2020/08/05 06:00 PHST- 2020/08/05 06:00 [pubmed] PHST- 2021/11/05 06:00 [medline] PHST- 2020/08/05 06:00 [entrez] AID - 10.1080/21681805.2020.1798502 [doi] PST - ppublish SO - Scand J Urol. 2020 Oct;54(5):401-407. doi: 10.1080/21681805.2020.1798502. Epub 2020 Aug 4.